Stashenko, et al. U.S.S.N. 10/734,692

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

(Currently Amended) A method of inhibiting osteoclast-mediated bone resorption in a bone cell, comprising inhibiting an activity of a gene product encoded by osteoclast associated gene OC14-comprising the nucleotide sequence of SEQ ID NO: 50 by administering a compound an antibody that decreases the activity of said gene product by at least 10% in the presence of said compound antibody, as compared to the activity of said gene product in the absence of said compound antibody, and wherein said compound is an antibody or an antisense polynucleotide.

2. - 26. (Cancelled)

- 27. (Currently Amended) The method of claim 1, wherein the activity of said gene product is decreased by at least 1.5-fold in the presence of said empeund antibody, as compared to the activity of said gene product in the absence of said empeund antibody.
- 28. (Currently Amended) The method of claim 1, wherein the activity of said gene product is decreased by at least 3-fold in the presence of said empound antibody, as compared to the activity of said gene product in the absence of said empound antibody.
- 29. (Currently Amended) The method of claim 1, wherein the activity of said gene product is decreased by at least 5-fold in the presence of said empound antibody, as compared to the activity of said gene product in the absence of said empound antibody.

(Cancelled)

31. (Currently Amended) The method of claim 1, wherein the activity of said gene product is decreased by at least 50% in the presence of said eompound antibody, as compared to the activity of said gene product in the absence of said eompound antibody.

Stashenko, et al. U.S.S.N. 10/734,692

- 32. (Currently Amended) The method of claim 1, wherein the activity of said gene product is decreased by at least 75% in the presence of said empound antibody, as compared to the activity of said gene product in the absence of said empound antibody.
- 33. (Currently Amended) The method of claim 1, wherein the activity of said gene product is decreased by at least 90% in the presence of said empound antibody, as compared to the activity of said gene product in the absence of said empound antibody.